The AstraZeneki vaccine weakens after 12 weeks. The project assumes a change of formulation in the second dose

People under 60 who were given as part of the first dose vaccine companies AstraZenecashould be moved to the queue waiting for another type of vaccine. This is a recommendation from the Standing Committee on Vaccination (Stiko) in a draft that was presented on Thursday, April 1.

The effect of AstraZeneki wears off after 12 weeks

Health Minister of Germany Jens Spahn The (CDU) wants to discuss the recommendation with the federal state health ministers next Wednesday. He said on Twitter: “Stiko’s revised recommendation on second immunization creates clarity for the approximately 2.2 million citizens under 60 who received AstraZeneca’s first vaccine in recent weeks.” The politician assured that these people would be able to receive an mRNA preparation (BioNTech or Moderna). It will start in mid-April, as AstraZeneca has only been in use in Germany from the beginning of February.

Watch the video
Dworczyk apologizes after the vaccine fuss. “The Minister of Health was not on yesterday’s headquarters”

Stiko’s draft recommendation states: “For these people, it is recommended that instead of a second dose of AstraZeneca vaccine be given the mRNA vaccine 12 weeks after the first vaccination. The reason is that the protection provided by AstraZeneki begins to weaken after 12 weeks.”

Better not to try

Stiko’s recommendation may affect a large number of people in Germany. According to data from the Robert Koch Institute, 2.85 million people had received an initial vaccination with AstraZeneca by April 1. Only less than 2,000 people were vaccinated with it for the second time.

Read more:  Next week peak on northern ICs: 'We can handle them quite well'

A wider circle of professions qualifying for vaccination. There is an amendment

Stiko chairman Thomas Mertens told Der Spiegel that the risks of the AstraZeneca vaccine can now only be speculated – as only a handful of people have already had it twice. “The solution, in my opinion, is not to try this at all, but to use an RNA vaccine as an alternative.”

MRNA vaccines approved for human use during a pandemic coronawirusa, is a completely new type of vaccine that uses messenger ribonucleic acid (mRNA) to deliver genetic information to cells to trigger the body’s defenses. This is to protect him from future infection.

Mertens said animal studies show that the immune response is the same when two different formulations are given. “How good this protection is for humans is still waiting to be clarified,” he added.

Some 40-year-olds have already taken the vaccine.  Dates were available yesterdaySome 40-year-olds have already taken the vaccine. Dates were available yesterday

Risk of thrombosis

The use of two different formulations to induce better defense mechanisms has been considered for a long time. For example, the first injection with AstraZeneki could be followed by a second dose from BioNTech / Pfizer. “From a purely immunological point of view this is not problematic because they ultimately rely on the same vaccine antigen,” said Christian Bogdan, an infectious immunologist and member of Stiko, recently. The effectiveness of the various combinations is currently under investigation.

On Tuesday 30 March, German authorities announced that, according to Stiko’s recommendation, the AstraZeneca vaccine should only be given to people over 60 years of age. This was due to 31 reported suspected cases of cerebral vein thrombosis. Of these, nine cases were fatal. Experts suspect that only young people are at risk.

Read more:  Sonnenberg wants to remove unknown giant Hunter Douglas from the stock exchange | Financial

The article comes from Deutsche Welle.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick